This site is intended for patients in Great Britain (England, Scotland and Wales) who have been prescribed PIQRAY®▼ (alpelisib) + fulvestrant.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

How do I take Piqray?

It is important to take your medication exactly as it was prescribed. Knowing how to take Piqray makes it easier to follow and manage your treatment schedule.1

Watch the short video below on how to take Piqray.


For more guidance, please refer to the leaflet inside your medication box (your Patient information leaflet) and your Piqray patient brochure.

To keep track of your treatment doses, you may find it useful to use the treatment tracker.

How to take your medication

It is important that you do not change your dose or stop taking your medication without talking to your doctor.1

How to take Piqray full width infographic

Warnings and Precautions¹

Do not take this medication if you are allergic to alpelisib or any of the other ingredients of this medicine (please see the Patient Information Leaflet in your Piqray medication box for a list of ingredients). If you think you may be allergic, ask your doctor for advice.1

Talk to your doctor or pharmacist before taking alpelisib.1

If any of the following apply to you before taking alpelisib, tell your doctor or pharmacist:1

  • If you have or have ever had high levels of sugar in your blood or diabetes (or signs of increased sugar levels, such as excessive thirst and dry mouth, needing to pass urine more often than usual, producing greater amounts of urine than usual, tiredness, nausea, increased appetite with weight loss)
  • If you have ever had Stevens-Johnson syndrome (SJS), erythema multiforme (EM), drug reaction with eosinophilia and systemic symptoms (DRESS) or toxic epidermal necrolysis (TEN)
  • If you have a severe bone disease that affects the jaw (osteonecrosis of the jaw, ONJ).

Pregnancy, breastfeeding and fertility1
Piqray must not be used by women who are, or may be, pregnant or breastfeeding. Alpelisib may harm an unborn baby. If you think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will discuss with you the potential risks of taking alpelisib during pregnancy or breastfeeding.

These are some of the important warnings and precautions related to Piqray. This is not an exhaustive list and the full list can be found in the patient information leaflet.1 There may be other symptoms that you experience that can also affect your treatment with Piqray. Make sure you read the patient information leaflet included with your medicine in full before starting treatment so that you are aware of any that may affect you.1 

What if I forget to take Piqray?¹

If it has been less than 9 hours since your regularly scheduled dose:

0-9 hours missed dose full width


If it has been more than 9 hours since your regularly scheduled dose:

9+ hours missed dose

What if I take more Piqray than I should?

People who have taken too many Piqray tablets may experience side effects such as high blood sugar levels, nausea, tiredness and rash. If you accidentally take too many tablets, or if someone else accidentally takes your medicine, contact a doctor or hospital for advice immediately, as medical treatment may be necessary.1

How should I store Piqray?

It is important to keep Piqray out of sight and reach of children. However, it does not require any special storage conditions.1

Resource banner image, woman on sofa

Browse through a range of helpful materials ranging from information about your diagnosis, Piqray treatment and living well with aBC

Where would you like to go next?


aBC, advanced breast cancer.


  1. PIQRAY® (alpelisib) Patient Information Leaflet. Available at: [Accessed November 2021].
  2. Faslodex (fulvestrant). Patient Information Leaflet. Available at: [Accessed November 2021].

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See for how to report side effects.

UK | January 2022 | 147268